Cargando…

P868: A CIRCULATING SERUM MIRNAS-BASED MODEL TO PREDICT EARLY MORTALITY IN MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-BASED REGIMENS.

Detalles Bibliográficos
Autores principales:	Puła, A., Robak, P., Jarych, D., Mikulski, D., Dróżdż, I., Szemraj, J., Robak, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429183/ http://dx.doi.org/10.1097/01.HS9.0000846352.00706.35

Ejemplares similares

The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
por: Puła, Anna, et al.
Publicado: (2023)

Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
por: Robak, Paweł, et al.
Publicado: (2021)

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients
por: Robak, Paweł, et al.
Publicado: (2020)

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
por: Robak, Paweł, et al.
Publicado: (2020)

Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib
por: Mikulski, Damian, et al.
Publicado: (2021)

The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib
por: Robak, Pawel, et al.
Publicado: (2021)

The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications
por: Puła, Anna, et al.
Publicado: (2021)

Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study
por: Mikulski, Damian, et al.
Publicado: (2022)

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
por: Robak, Pawel, et al.
Publicado: (2019)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
por: Urbańska-Ryś, Halina, et al.
Publicado: (2003)

Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients
por: Wang, Hua, et al.
Publicado: (2016)

PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives
por: Hus, Iwona, et al.
Publicado: (2022)

Editorial: Novel targeted drugs for indolent lymphoid malignancies
por: Robak, Tadeusz, et al.
Publicado: (2023)

Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma
por: Kim, Kihyun, et al.
Publicado: (2013)

Bortezomib-Based Regimens and Plasma Cell Leukemia
por: Bolaman, Ali Zahit
Publicado: (2021)

Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

Clinical significance of circulating dendritic cells in patients with systemic lupus erythematosus.
por: Robak, E, et al.
Publicado: (2004)

Fungal Planet description sheets: 868–950
por: Crous, P.W., et al.
Publicado: (2019)

Clinical outcomes of bortezomib-based therapy in myeloma
por: Djebbari, Faouzi, et al.
Publicado: (2018)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
por: Robak, T, et al.
Publicado: (1998)

Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients
por: Zhou, Qiaolin, et al.
Publicado: (2022)

Circulating TCR gammadelta cells in the patients with systemic lupus erythematosus.
por: Robak, E, et al.
Publicado: (1999)

Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.
por: Robak, Ewa, et al.
Publicado: (2003)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimens
por: Kakoo, Ashraf, et al.
Publicado: (2022)

Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma
por: Robak, Marta, et al.
Publicado: (2012)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
por: He, Jingsong, et al.
Publicado: (2020)

Circulating Total and Active Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Systemic Lupus Erythomatosus
por: Robak, Ewa, et al.
Publicado: (2006)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
por: Qian, Wensi, et al.
Publicado: (2020)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety
por: Zhai, Yujia, et al.
Publicado: (2021)

New bortezomib-based combination therapy for elimination of myeloma cells
por: Meister, S, et al.
Publicado: (2009)

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
por: Richardson, Paul G., et al.
Publicado: (2021)

Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma
por: Maekawa, Keiko, et al.
Publicado: (2019)

Estimation of SLE activity based on the serum level of chosen cytokines and superoxide radical generation.
por: Waszczykowska, E, et al.
Publicado: (1999)

Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
por: Robak, Ewa, et al.
Publicado: (2022)

Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance
por: Robak, Tadeusz, et al.
Publicado: (2022)

Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients
por: Ting, Kay Reen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7iae4okf81th39t3gc803gqnf9